Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of Nomlabofusp in Friedreich's Ataxia
NCT04519567Phase 1Completed
- Sponsor
- Larimar Therapeutics
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich ataxia (FA) comparing CTI-1601 (Nomlabofusp) with Placebo (2 arms). Primary endpoints: Number of Participants with Treatment Emergent Adverse Events and Number of Participants with Treatment Emergent Adverse Events by System Organ Classification and Preferred Term. Started Jul 2020; status: completed.
02
Drugs
nomlabofusp
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT04519567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519567.